Analysis-Sanofi’s COVID-19 vaccine setback, drug pipeline cast long shadow

By Matthias Blamont
PARIS (Reuters) – Pharmaceutical company Sanofi remains under pressure to launch new drugs and overcome setbacks in the COVID-19 vaccine race, despite a $3.2 billion deal to tighten its grip on promising mRNA technology.
On Tuesday,…

Click here to view the original article.